As of April 19, 2025, Inhibrx (INBX) has a market cap of $0.17 billion USD. According to our data, Inhibrx is ranked No.7175 in global market value.
Year | Market Cap | %Change |
---|---|---|
Apr 19, 2025 | $0.17 B |
-25.52%
|
Dec 31, 2024 | $0.22 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
![]() Amgen
AMGN
|
$149.09 B |
0.124 B
|
![]() USA
|
![]() Regeneron Pharmaceuticals
REGN
|
$61.57 B |
1.023 B
|
![]() USA
|
![]() Gilead Sciences
GILD
|
$130.32 B |
-0.001 M
|
![]() USA
|
![]() Biogen
BIIB
|
$17.36 B |
-0.001 M
|
![]() USA
|
![]() Vertex Pharmaceuticals
VRTX
|
$125.74 B |
-0.003 M
|
![]() USA
|
![]() Moderna
MRNA
|
$9.56 B |
-0.000 M
|
![]() USA
|
![]() BioMarin Pharmaceutical
BMRN
|
$11.35 B |
0.000 M
|
![]() USA
|
![]() Alnylam Pharmaceuticals
ALNY
|
$30.36 B |
0.000 M
|
![]() USA
|
![]() Sarepta Therapeutics
SRPT
|
$5.22 B |
0.000 M
|
![]() USA
|
![]() bluebird bio
BLUE
|
$40.53 M |
0.000 M
|
![]() USA
|
![]() CRISPR Therapeutics
CRSP
|
$3.26 B |
0.000 M
|
![]() Switzerland
|
![]() Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
![]() USA
|
![]() Intellia Therapeutics
NTLA
|
$0.75 B |
-0.000 M
|
![]() USA
|
![]() Sangamo Therapeutics
SGMO
|
$0.16 B |
-0.989 M
|
![]() USA
|
Market Cap | = | INBX Stock Price | * | INBX Shares Outstanding |
= | $11.47 | * | 14.48 M | |
= | $0.17 B |